Search clinical trials for: Atomoxetine hydrochloride

Total 7331 results

Norwegian University of Science and Technology
St. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...

Recruiting

Bariatric Surgery and Pharmacokinetics of Atomoxetine

Obesity, Morbid

Norway
Eli Lilly and Company

Completed

A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Spain, France, Austria, Germany, Belgium, Finland, Italy, Netherlands, Portugal, Sweden, Switzerland, United Kingdom
Eli Lilly and Company

Completed

Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease

Alzheimer Disease

United States
Eli Lilly and Company

Completed

Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

Attention Deficit Hyperactivity Disorder | Comorbid Social Anxiety Disorder

United States, Puerto Rico
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA)

Completed

Effectiveness of ATMX in Treating Adolescents With ADHD and SUD

Substance-Related Disorders | Attention Deficit Disorder With Hyperactivity

United States
Eli Lilly and Company

Completed

Long-Term Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder (AD/HD)

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Korea, Republic of
Eli Lilly and Company

Completed

Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) With Atomoxetine in Young Adults and Its Effects on Functional Outcomes

Attention Deficit Hyperactivity Disorder

United States, Puerto Rico
Eli Lilly and Company

Completed

Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD

Attention Deficit Hyperactivity Disorder | Oppositional Defiant Disorder

Australia, Belgium, Denmark, Finland, Germany, Netherlands, Spain, United Kingdom
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject

Depression
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subjects

Depression

China
Eli Lilly and Company

Completed

An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).

Attention Deficit Hyperactivity Disorder | Oppositional Defiant Disorder

Italy
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)

Terminated

Safety Assessment of Atomoxetine With MA IV Administration

Methamphetamine Dependence | Methamphetamine Abuse

United States
National Institute on Drug Abuse (NIDA)
University of Pennsylvania

Completed

Atomoxetine for the Treatment of Cannabis Dependence

Cannabis Dependence

United States
Eli Lilly and Company

Completed

Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD

Attention-Deficit/Hyperactivity Disorder | Comorbid Dyslexia

United States
Eli Lilly and Company

Completed

Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

Attention-Deficit/Hyperactivity Disorder

Canada
Eli Lilly and Company

Completed

Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Canada
Lindner Center of HOPE
University of Cincinnati

Completed

Atomoxetine in the Treatment of Binge Eating Disorder

Binge-eating Disorder

United States
Poitiers University Hospital

Terminated

Atomoxetine in Patients With Tourette's Syndrome (ATO-TS)

Tourette Syndrome

France
NYU Langone Health
Eli Lilly and Company

Completed

Atomoxetine/Attention Deficit/ Hyperactive Disorder (ADHD)/Substance Use Disorder (SUD)in a Residential Treatment Facility

Attention Deficit Hyperactivity Disorder
Yale University
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine Effects in Humans

Physiological Stress
Peking University

Unknown

Associated Genes With Atomoxetine Response in Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

China
Central Institute of Mental Health, Mannheim
Heidelberg University

Completed

Driving in Adults With Attention-deficit/Hyperactivity Disorder (ADHD) Before and During Treatment With Atomoxetine (DrivPerfATX)

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

An Open-Label Study of Atomoxetine in Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

An Open-Label Study of Atomoxetine in Children With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Germany
Eli Lilly and Company

Completed

Maintenance of Benefit With Atomoxetine Hydrochloride in Adolescents With ADHD

Attention-Deficit/Hyperactivity Disorder

United States
Rhode Island Hospital
Eli Lilly and Company

Unknown

Effect of Atomoxetine on ADHD-Related Insomnia in Children and Adolescents

Insomnia | Attention-Deficit/Hyperactivity Disorder (ADHD)

United States
Apnimed

Completed

Trial of AD113 and Atomoxetine in OSA Patients With Hypertension

Hypertension | Obstructive Sleep Apnea

United States
New York State Psychiatric Institute
National Institute on Drug Abuse (NIDA)

Completed

Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder

Marijuana Abuse | Attention Deficit Disorder With Hyperactivity

United States
Massachusetts General Hospital
National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH)

Withdrawn

Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD

Substance Use Disorder | Attention Deficit Hyperactivity Disorder

United States
Monarch Medical Research
Eli Lilly and Company

Terminated

Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for ALL

Attention Deficit Hyperactivity Disorder

United States
Rhode Island Hospital

Completed

The Effect of a Once Daily Dose of Atomoxetine (ATX) on ADHD-Related Insomnia in Children and Adolescents

Insomnia | Attention Deficit Hyperactivity Disorder

United States
Eli Lilly and Company

Completed

Efficacy, Tolerability, and Safety of Once-Daily Atomoxetine Hydrochloride Versus Placebo in Russian Children and Adolescents With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Disorder With Hyperactivity

Russian Federation
Eli Lilly and Company

Completed

Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents

Attention Deficit Hyperactivity Disorder

Sweden
Yale University
VA Office of Research and Development

Withdrawn

Atomoxetine's Effects On Nicotine Response And Stress Response In Smokers

Nicotine Dependence

United States
University of Pennsylvania
Eli Lilly and Company

Completed

Placebo Controlled Study of Atomoxetine in the Treatment of Mild to Moderate Cognitive Difficulties in Menopausal Women

Menopause | Cognitive Disturbances

United States
Denver Health and Hospital Authority
American Academy of Child Adolescent Psychiatry.

Completed

Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder

Attention Deficit Hyperactivity Disorder | Substance Abuse

United States
University of Arizona

Completed

Autonomic Correlates of Impulsivity for Preschool Children With Attention Deficit Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder
Eli Lilly and Company

Completed

Treatment of ADHD With Atomoxetine in Children & Adolescents With ADHD & Comorbid Dyslexia

Attention Deficit Hyperactivity Disorder | Dyslexia

United States
Apnimed

Completed

Crossover Trial of AD036 in Obstructive Sleep Apnea

Obstructive Sleep Apnea

United States
Eli Lilly and Company

Completed

Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia

Attention Deficit Hyperactivity Disorder | Dyslexia

United States
University of Calgary
Cardiac Arrhythmia Network of Canada

Completed

Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope (POST6)

Vasovagal Syncope

Canada
Massachusetts General Hospital
Eli Lilly and Company

Completed

Strattera Treatment in Adults With Attention Deficit Hyperactivity Disorder Not Otherwise Specified (ADHD NOS)

ADHD NOS

United States
Craig Hospital

Completed

Efficacy Study of Strattera for Treating Attention Disorders in Traumatic Brain Injury (TBI)

Traumatic Brain INjury

United States
Eli Lilly and Company

Completed

A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder

Attention Deficit Hyperactivity Disorder

Korea, Republic of, Taiwan, Japan
Eli Lilly and Company

Completed

Atomoxetine Phase 2 Study in Japanese Adult Patients With Attention Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Japan
Eli Lilly and Company

Completed

Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder

Germany
RWTH Aachen University

Completed

Network Connectivity and Inhibitory Control Under Atomoxetin Challenge- A Pharmacological 'Resting State' and 'Inhibiton Task' Study in Patients With ADHD (CAIAC)

ADHD

Germany

Search clinical trials for: Atomoxetine hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations